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SATU PENYIASATAN KLINIKAL DAN FARMAKOGENETIK TERHADAP 
RAWATAN PENGEKALAN METADON (MMT) DI KALANGAN INDIVIDU 
PENGGUNA OPIAT 
  
ABSTRAK 
 
Sehingga kini terdapat banyak penemuan yang telah merevolusikan bidang perubatan. 
Metadon telah merevolusikan pengurusan pengguna opiate. Melalui MMT, kebanyakan 
pesakit memberikan respon yang baik dan menunjukkan peningkatan dari segi taraf 
kesihatan. Walaubagaimanapun, sifat farmakologinya yang kompleks dan pemikiran 
“opiophobia”telah membataskan kegunaannya. Di kalangan “opiophobics” ini, 
penggunaan ubatan Cina telah menarik perhatian mereka untuk menggunakannya sebagai 
rawatan alternatif. Kami telah melakukan kajian klinikal dan makmal terhadap faktor-
faktor yang terlibat dalam meramal kejayaan program MMT, sebagai satu langkah untuk 
membaik pulih rawatan dengan metadon dan untuk membantu kami merangka satu 
panduan untuk mengoptimakan MMT. Kami juga mengkaji kesan herba Cina, BioLitrin 
ke atas pesakit yang telah distabilkan dengan MMT bagi menilai peranannya sebagai 
tambahan kepada MMT. 
 
Bahan dan Kaedah 
Kajian klinikal ini telah menerima kelulusan etika daripada Pusat Perubatan Universiti 
Malaya di Kuala Lumpur dan Universiti Sains Malaysia di Kelantan. Kajian ini 
melibatkan dua komponen iaitu kajian klinikal dan kajian makmal farmakogenetik. 
Kajian klinikal melibatkan 2 fasa.  
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Dalam kajian klinikal fasa 1, pesakit MMT yang hadir ke Klinik Khafiz di Semenyih dan 
Klinik SAHABAT di Kota Bharu yang telah memberikan persetujuan dan memenuhi 
kriteria kajian kami telah dijemput untuk menyertai kajian ini. Mereka telah mengambil 
metadon secara harian berdasarkan panduan yang disediakan oleh Kementerian 
Kesihatan Malaysia. Parameter-parameter klinikal dan makmal pula dipantau 
berdasarkan protokol kajian kami. Di sepanjang tempoh kajian tersebut, mereka telah 
melalui rawatan susulan selama 12 bulan. Kepelbagaian genetik pada lokus-lokus gen 
CYP2B6, reseptor opiat-µ, dan CYP3A4 telah  dikenalpasti dengan mengekstrakkan DNA 
daripada subjek-subjek menggunakan kit mini QIAgen DNA. Bagi CYP3A4, kaedah 
nested allele Polimerasi Tindak Balas Berantai (PCR) yang spesifik telah diaplikasikan 
untuk mengesan jenis dan frekuensi-frekuensi alel yang berikut: CYP3A4*1B, 
CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*7, CYP3A4*8,  CYP3A4*9, 
CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14,  CYP3A4*15,  
CYP3A4*16. Manakala bagi alel CYP2B6 (CYP2B6*2 dan CYP2B6*9 ) dan OPRM1       
( G31A, G691C dan A118G ) pula, kaedahnya adalah dengan menggunakan Kit 
“Personalized Medicine for Methadone” yang telah dicipta di Institut Penyelidikan 
Perubatan Molekul (INFORMM). Kit ini juga telah digunakan untuk mengenalpasti 
plasma metadon. DNA daripada kawalan normal yang terdiri daripada orang Melayu, 
Cina dan India juga telah dikenalpasti untuk kepelbagaian genetik pada lokus-lokus 
seperti di atas. 
Dalam kajian klinikal fasa II, seramai 40 orang pesakit yang telah memberikan 
persetujuan dan memenuhi kriteria kajian kami telah menyertainya. Setiap daripada 
mereka pada permulaannya menerima sama ada dua kapsul yang mengandungi 200 mg 
  
xvii 
BioLitrin diambil 2 kali sehari atau dua kapsul mengandungi ”placebo” bersama-sama 
dengan metadon pada dos yang tetap sebanyak 40 mg selama 4 minggu berturut-turut. 
Darah juga diambil untuk mengesan paras plasma metadon dan kualiti tidur serta skor 
tarikan opiat diukur dan dibandingkan. Selepas ”wash-out period” selama dua minggu, 
penukaran telah dilakukan, di mana pesakit-pesakit yang telah menerima Biolitrin pada 
permulaannya kini telah diberikan ”placebo”, manakala pesakit-pesakit yang dahulunya 
menerima ”placebo” kini menerima Biolitrin. 
 
Keputusan  
 
Seratus dua puluh lapan orang pesakit telah menyertai fasa I kajian klinikal. Seterusnya 
40 orang pesakit dikaji di dalam fasa II Secara umumnya, kadar kekal (retention rate) 
pada 12 bulan adalah 54.69% dengan 58 pesakit telah hilang semasa rawatan susulan. 
Daripada mereka yang masih “kekal”, 80% daripadanya telah menerima dos sebanyak 80 
mg atau lebih  sehari. Tiada di antara mereka yang berada dalam kumpulan dos 0 – 39 
mg  sehari. Kadar kekal untuk kumpulan dos 40 – 79 mg sehari pula adalah sebanyak 
20%. Perbezaan di antara kumpulan dos-dos ini dari segi kadar kekal dan injeksi semula 
mencapai statistik  yang signifikan, (masing-masing adalah p<0.001, p<0.001). Purata 
dos harian pula ialah 57.2 mg (SD ± 22.7) dan berada dalm lingkungan 20 to 160 mg 
sehari, iaitu perbezaan sebanyak lapan kali ganda. Purata kepekatan plasma metadon 
berkenaan pula adalah 281.3 ng/ml (SD ± 567.9) dan berada dalam lingkungan 0 to 4634 
ng/ml. Di antara  pesakit yang menerima dos harian tetap metadon pada 40 mg, plasma 
metadonnya adalah berbagai dari 14 ng/ml ke 331 ng/ml, iaitu perbezaan sebanyak 23 
kali ganda. Dalam kajian klinikal fasa II, purata SOW adalah 32 ( SD ± 10.4) dan dalam 
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lingkungan 11 ke 51. Purata OOW pula adalah 8.2 ( SD ± 1.5 ). Pada lokus CYP2B6,  7% 
adalah heterozigus CYP2B6*1A / CYP2B6*2 (64 C/T). Pada G15631T pula, 51.3% 
adalah homozigus CYP2B6*1A (15631 G/G), 39.1% adalah heterozigus CYP2B6*1A / 
CYP2B6*9 (15631 G/T) dan 9.6% adalah homozigus mutasi  CYP2B6*9. Frekuensi-
frekuensi bagi CYP2B6*2 dan CYP2B6*9 masing-masing adalah 3.5 dan 29.1. Daripada 
17 alel yang telah diuji untuk gen reseptor opiat-µ, frekuensi pada alel-alel G31A, 
G691C dan A118G masing-masing adalah 3.9, 20.9 dan 56.1. Sejumlah besar pesakit 
adalah pembawa alel CYP2B6 iaitu alel yang boleh memberikan petunjuk tentang  
metabolism metadon yang rendah. Selain itu, sejumlah besar pesakit yang lain juga 
adalah pembawa alel reseptor opiat-µ mutasi, yang mana boleh memberikan ramalan 
mengenai kesan opiat yang kurang baik. Subjek kawalan kesemuanya membawa gen 
“wild type”. Alel mutasi pada CYP3A4*1B pula telah dijumpai dalam 2.17% subjek-
subjek pengguna opiat.  
Pada kajian klinikal fasa II, plasma metadon adalah lebih rendah daripada sasaran 400 
ng/ml dalam kebanyakan keadaan dalam kebanyakan pesakit. Tiada kepekatan plasma 
metadon yang diperolehi melebihi 700 ng/ml, di mana ia boleh dianggap sebagai had atas 
untuk plasma metadon. Purata SOW dalam pesakit yang menerima hanya metadon sahaja 
adalah 32 dan dalam pesakit yang menerima gabunngan metadon dan BioLitrin 
puratanya adalah 3.5, iaitu perbezaan sebanyak sepuluh kali ganda. Purata OOW dalam 
“placebo” adalah 8.2 dan semasa mengambil BioLitrin adalah 0.7, iaitu perbezaan 
sebanyak lebih daripada sepuluh kali ganda. Semasa mengambil BioLitrin pesakit 
mengalami kurang tarikan berbanding semasa  ”placebo” dan ini mencapai perbezaan 
statistik yang signifikan. 
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Kesimpulan 
 
Walaupun metadon ada potensi untuk merevolusikan perawatan penggunaan opiat, sifat 
farmakologinya yang kompleks dan pemikiran ”opiophobia” yang meluas telah 
membataskan keberkesanannya. Kami menggunakan kit diagnosa yang telah dicipta di 
INFORMM untuk mengesan kepelbagaian CYP2B6 dan reseptor opiat-µ dan juga untuk 
mengukur plasma metadon. Selain daripada mencari kaedah untuk mengesan variasi 
CYP3A4 , kami juga mentakrifkan kepelbagaian genetik CYP3A4 . Kami juga telah 
menyiasat rawatan yang menggabungkan metadon dan BioLitrin. Dos-dos harian 
metadon,paras metadon dalam plasma, kadar kekal dan injeksi semula adalah pelbagai. 
Walaubagaimanapun,  maklumat diperolehi mengenai kepelbagaian pada lokus-lokus 
CYP2B6, reseptor opiat-µ dan CYP3A4 yang diperolehi daripada kajian ini adalah tidak 
mencukupi untuk merekacipta rejimen dos metadon. Ramalan yang paling bagus ke atas 
keberkesanan MMT boleh dilakukan dengan mengambil dos harian yang melebihi 80 
mg. Dalam kebanyakan pesakit, plasma metadonnya adalah tidak berguna tetapi di dalam 
sesetengah kes tertentu, plasma metadon boleh digunakan untuk perawatan dalam kes 
kegagalan terapeutik. BioLitrin boleh bertindak secara sinergistik bersama metadon. Ia 
membantutkan tarikan dan meningkatkan kualiti tidur. Seterusnya, kajian susulan 
diperlukan untuk menggabungkan BioLitrin dan metadon terutamanya untuk kegunaan 
jangka masa panjang. Kajian yang lebih besar juga diperlukan untuk mengenalpasti lebih 
banyak kegunaan kit ”Personalised Medicine for Methadone” dalam pengurusan rutin 
MMT. 
Kata Kunci:  MMT, kekal, variasi kepekatan plasma metadon, Biolitrin, kualiti tidur, 
skor tarikan opiat, farmakogenetik, CYP2B6, OPRM1 dan CYP3A4. 
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A CLINICAL  AND  PHARMACOGENETIC  INVESTIGATION  OF 
METHADONE  MAINTENANCE  THERAPY (MMT)  IN  OPIATE 
DEPENDENT  INDIVIDUALS. 
 
ABSTRACT 
 
Over time, many discoveries revolutionized medicine. Methadone has revolutionized the 
management of opiate dependence. With MMT, most patients respond well and their 
health improves. Its complex pharmacology and “opiophobia” however impede its full 
usefulness. Among the “opiophobics”, alternative therapies with, as an example, Chinese 
medicines, are frequently sought and advocated. We performed a laboratory and clinical 
study with the objective of investigating factors that predict successful MMT program, in 
an effort to improve therapy with methadone and to help us develop guidelines on the 
optimization of MMT. We also studied the effect of a Chinese herb, BioLitrin in patients 
maintained on MMT to evaluate its role as an adjunct to MMT. 
 
Materials and Methods: 
The study received ethical approvals from University Malaya Medical Centre in Kuala 
Lumpur and Universiti Sains Malaysia in Kelantan. The study consisted of both Clinical 
and Pharmacogenetic laboratory components. The clinical studies involved 2 phases. 
In phase I clinical study, MMT patients attending Klinik Dr Khafidz in Semenyih and 
Klinik SAHABAT in Kota Bharu who consented and met our study criteria participated 
in the study. They took their daily methadone according to guidelines of the Malaysian 
Ministry of Health. Laboratory and clinical parameters were monitored based on our 
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study protocols. They were followed up for 12 months of study period. The genetic 
polymorphisms at the CYP2B6, µ-opioid receptor and CYP3A4 gene loci were 
determined from subjects’ DNA extracted using QIAgen DNA mini kit. For CYP3A4 a 
nested allele specific PCR was applied to detect the types and frequencies of the 
following allele: CYP3A4*1B, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, 
CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, 
CYP3A4*13, CYP3A4*14, CYP3A4*15 and CYP3A4*16. For the allele of CYP2B6 
(CYP2B6*2 and CYP2B6*9), and OPRM1 (G31A, G691C and A118G) the Personalized 
Medicine for Methadone Kit developed at Institute for Research in Molecular Medicine 
(INFORMM) was used. This kit was also used to determine plasma methadone. DNA 
from Malay, Chinese and Indian normal controls were also determined for genetic 
polymorphisms at the above loci. 
 
In phase II, 40 patients who met our study criteria and who consented participated. Each 
initially received either 2 capsules containing 200 mg BioLitrin twice a day or two 
capsules containing placebo together with a fixed dose of methadone, 40 mg daily for 4 
consecutives weeks. Blood for plasma methadone level was obtained and sleep quality 
and opiate withdrawal scores were measured and compared. After a two-week wash out 
period, a switch over was done with the patients initially receiving BioLitrin now given 
placebo and patient initially given placebo now given BioLitrin. 
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Results: 
 
One hundred and twenty eight patients were enrolled in Phase I. A further 40 patients 
were studied Phase II. Overall retention rate at the 12-month was 54.69% with 58 
patients lost to follow up. Of the “retained” patients, 80% were receiving 80 mg or more 
per day. None was found in the 0 – 39 mg per day dose group. Retention rate for the     
40 – 79 mg per day dose group was 20%. The differences between the dose groups in 
terms of retention rates and re-injection reached statistical significance (p<0.001, 
p<0.001 respectively). Daily dose averaged 57.2 mg ( SD ± 22.7 ) and ranged from 20 to 
160 mg per day, an 8-fold difference. The corresponding plasma methadone 
concentration averaged 281.3 ng/ml ( SD ± 567.9 ) and ranged from 0 to 4634 ng/ml. 
Plasma methadone among patients at fixed 40 mg daily methadone dose varied from     
14 ng/ml to 331 ng/ml, a 23-fold difference. In phase II clinical study, SOW averaged 32 
( SD 10.4 ) and ranged from 11 to 51. OOW averaged 8.2 ( SD ±1.5).  At the CYP2B6 
locus, 7% were heterozygous CYP2B6*1A / CYP2B6*2 (64 C/T). For G15631T, 51.3% 
were homozygous CYP2B6*1A (15631 G/G), 39.1% heterozygous CYP2B6*1A / 
CYP2B6*9 (15631 G/T) and 9.6% homozygous mutant CYP2B6*9. The frequencies for 
CYP2B6*2 and CYP2B6*9 were 3.5 and 29.1. Of the 17 alleles tested for µ-opioid 
receptor gene, the frequencies for the following G31A, G691C, and A118G alleles were 
3.9, 20.9, and 56.1, respectively. A significant proportion of the patients carried CYP2B6 
alleles that predicted reduced methadone metabolism. Similarly a significant proportion 
carried µ- receptor mutants that predicted poor opiate effect. Control subjects all carried 
  
xxiii 
the wild-type gene. Mutant CYP3A4*1B allele on the other hand was found in 2.17% of 
opiate-dependent subjects. 
 
In phase II plasma methadone were lower than the desired 400 ng/ml in most instances in 
most patients. None of the plasma methadone concentrations obtained was above 700 
ng/ml, a suggested upper limit for plasma methadone. SOW in methadone alone patients 
averaged 32 and in methadone with BioLitrin patients averaged 3.5, a 10-fold difference. 
OOW during placebo averaged 8.2 and during BioLitrin 0.7, a more than 10-fold 
difference. During BioLitrin, patients suffered much less withdrawal compared to during 
placebo and this difference reached statistical significance. 
 
Conclusion 
Although methadone has the potential to revolutionize the management of opiate 
dependence, its complex pharmacology and a generalized “opiophobia” impede its 
effectiveness. We used a diagnostic kit developed at INFORMM to detect CYP2B6 and 
µ-opiate receptor polymorphisms and to measure plasma methadone. Coupled with a 
method for the detection of CYP3A4 variants, we also defined the genetic polymorphisms 
of CYP3A4. We also investigated combined methadone and BioLitrin therapy. Daily 
methadone doses, resulting plasma methadone and retention and re-injecting rates varied. 
Information on the genetic polymorphisms at the CYP2B6, µ-opiate receptor and 
CYP3A4 loci from this study was not sufficient to design methadone dosage regimens. 
Best prediction for MMT effectiveness was provided by a daily dose in excess of more 
than 80 mg. In the average patient, plasma methadone was not useful but in selected 
  
xxiv 
patients, plasma methadone can be used to manage therapeutic failures. BioLitrin acted 
synergistically with methadone. It inhibits withdrawal and improved sleep quality. 
Further work is needed with BioLitrin with MMT, especially on its long term usefulness. 
Larger studies are also needed to better define the usefulness of the Personalized 
Medicine for Methadone kit in the routine management of MMT. 
 
 
Keywords:  MMT, retention, re-injecting, variable concentration of plasma  methadone 
level, BioLitrin, Sleeping quality, Opiate Withdrawal Score, Pharmacogenetic, CYP2B6, 
OPRM1 and CYP3A4. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 An Overview of the drug situation in Malaysia 
 
The proximity of Malaysia to the “Golden Triangle” makes Malaysia especially 
vulnerable to drug use problems and Malaysia has been grappling with the issues for 
decades now. As it is elsewhere, drug problem in Malaysia is not just a social and health 
problem. It has transgressed into multiple sectors; health, economic, social-justice and 
indeed it is threatening the very fabric of the society especially as it is now known as the 
driver for the growing HIV epidemic in the country. 
 
In Malaysia, traditionally, the illicit drug of choice is opiate-based drugs (heroin and 
morphine) and marijuana. Although the Government has vowed to make Malaysia “drug-
free” by 2015, in the past decade, annually the government identified more than 35,000 
drug dependent cases in the country (on the average, 55% relapse cases)‏ but this number 
seemed to have reduced in the past few years to about 25,000 cases reported annually. 
(National Anti Drug Institution Report, 2008). 
 
1.1.1 Opiate Distribution in Malaysia 
 
There are three main areas (triangle) that supplies drugs throughout the world. There are 
the Emerald Triangle which includes Columbia-Mexico-Peru, mainly distributing into the 
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USA and Canada; the Golden Crescent which includes Afghanistan-Iran-Pakistan and 
mainly distributing into Europe, Asia, Africa and the USA and the Golden Triangle 
which includes Myanmar-Laos-Thailand, mainly distributing into South East Asia, other 
parts of Asia, Australia and Africa. 
 
In Malaysia, the most commonly abused opiate is Heroin, followed by morphine, codeine 
and cannabiss. The supply of heroin is mainly from the Golden triangle. The majority of 
users are concentrated in West Malaysia but lately, opiate abuse started to establish itself 
in East Malaysia. 
 
In 2008, there were 4,974 recorded heroin users, 3,640 morphine users and 70 codeine 
users. Most of them (67.91%) were at their fertile and productive age (age of 20-39 year-
old), followed by 28.22% between the ages of 40-59 year-old and  3.87% aged less than 
19 year-old (National Anti Drug Institution Report, 2008). Reasons given for why they 
were involved with drugs were: influenced by friends (55.0%), for excitement and 
stimulant (22.1%), out of curiosity (14.7%), depression (6%), as pain killer (0.6%) and 
incidental (1.6%). Educational level does not seem to influence the potential for drug 
abuse. On study done in 2008 found that most users (96%) belonged to those with 
education at the SPM (Sijil Pelajaran Malaysia and below) level (National Anti Drug 
Institution Report, 2008). 
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1.1.2 Evolution of National Anti Drug Policy 
 
Government drug policy has changed over time to suit culture, norms, environment and 
of late, prevailing evidence. It evolved from the pre-independence to 1980 approach 
which saw the Dangerous Drug Act (1952) enacted based on the perceived correlation 
between drug use and criminal activities.  Drug addiction was also then looked at as a 
social problem which required treatment, rehabilitation and care under the purview of the 
Social Welfare Department. In 1983, the drug epidemic escalated drastically and drug 
addiction was declared as a security problem. The Drug Dependants (T &R) Act 1983 
was passed by Parliament to focus on mandatory drug treatment with the setting up of the 
Drug Treatment and Rehabilitation Department. A mandatory drug treatment in Pusat 
Serenti using the “tough and rugged” philosophy with a combination of health, 
psychosocial, occupational, religious and civic approaches was attempted and private 
drug treatment facilities were registered. (National Anti Drug Institution Report, 2008). 
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Loss of life through overdose and drug-related illness
Treatment of overdose and other medical  consequences of drug use
Community loss due to criminal activity
Law enforcement and judicial costs
Loss of quality of life for users and their families 
HIV & HepC
DRUG
 
Figure 1.1: The many harms of drug use disorder 
 
Beginning in 2000, the focus was to embrace the term drug dependant, and to be aware 
that there is drug misuse and abuse, and its relationship to criminal activities. Drug 
addiction was also redefined as a disease that must be treated as a chronic recurring 
disease, to keep up with current knowledge. In 2004, the NADA Act 2004 was approved 
to provide for continuity of rehabilitation and after care in the community. In terms of the 
overall approach to the drug problem, three approaches have been advocated. They are 
supply reduction meant to eliminate the supply of drugs into the country by sharing 
information/intelligence,  regional and international collaboration targeted at drugs and 
crimes, demand reduction to focus on treatment and rehabilitation (abstinence-based) in 
treatment institutions and community-based programmes, primary prevention with 
community involvement, and relapse prevention and subsequently in 2005, harm 
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reduction programme was implemented. Harm reduction is an intermediate goal in the 
treatment drug dependence. Harm reduction is a way of dealing with behavior that 
damages the health of the person involved and of their community. Harm reduction tries 
to improve individual and community health. Drug use won't disappear but its harmful 
effects can be reduced. Harm reduction should be a goal for service organizations and 
governments. Some drugs are safer than others. Some ways of using drugs are less 
harmful than others. Drug users can best reduce the harm of their own drug use. With 
harm reduction, the initial goals of the treatment of opiate dependence can be 
summarized as follows: reducing the use of illicit drugs; reducing the risk of infectious 
disease; improving physical and psychological health; reducing criminal behaviour; 
reintegration in the labour and educational  process; and improving social functioning, all 
without necessarily ceasing drug use. There are many components of harm reduction and 
programs may vary from place to place. They include outreach activities to provide risk 
reduction information, to educate on and provide condoms, bleach and clean needles, to 
provide referrals to treatment programs including primary health care’ to provide HIV 
testing and counseling, treatment of HIV/AIDS and shelter and food. It involves teaching 
drug users about the risks of different drugs and how they are used and providing 
information on using drugs more safely, and reducing the harm of overdoses. In more 
advanced centre, it provides methadone as a substitute for heroin and medications to 
counteract a drug overdose. Education and referral to drug treatment opportunities are 
also provided and some programs permit drug users to exchange used syringes, or buy 
new syringes. Outreach services are also provided in areas where drug sales occur so that 
it will bring it to the core of the problem. At SAHABAT, harm reduction involves the 
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needle-syringe exchange programme (NSEP) and methadone mantainance therapy. Harm 
reduction involves the needle-syringe exchange programme (NSEP) and methadone 
mantainance therapy (MMT) to substitute opiate with methadone. 
 
1.2 Intravenous Illicit Opioid Injection, HIV/AIDS and Blood Borne-Infections in 
Malaysia 
 
Opioid dependence and injecting drug use is a serious problem world-wide. It has been 
estimated that close to 15 million people world-wide are opioids user, with some 10 
million using heroin. This is a staggering 0.2 % of the world’s total population. As the 
global epidemic of heroin use continues, it adds an increasing burden, driving the AIDS 
epidemic in Malaysia and other parts of Asia, with consequent additional health, 
economics and social problems. 
 
The primary modes of transmission of HIV have changed little
 
over the years: 
unprotected intercourse, unprotected penetrative
 
sex between men, injection-drug use, 
unsafe injections and blood
 
transfusions, and transmission from mother to child during 
pregnancy,
 
labor and delivery, or breast-feeding. Direct blood contact,
 
such as the sharing 
of drug-injection equipment, is a particularly
 
efficient means of transmitting the virus. In 
parts of
 
China, India, Thailand, Vietnam and Malaysia, the epidemic is being
 
driven 
primarily by injection-drug use.  It is projected that the number of people infected with 
HIV in the Asia Pacific region will increase to thirty million by 2010 with Malaysia 
having the distinction of being a country with the fastest growing HIV epidemic in the 
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region. Asia appears set to take over from Africa as the global epicentre of the AIDS 
epidemic. This poses threats to our already struggling economy, our stability and even 
our national security as more people succumb to the disease, lose their jobs and become 
poorer. The sharing of injecting equipment is an efficient means of not only HIV 
transmission. It is also now the dominant means of transmission of hepatitis C. Hepatitis 
C results in a chronic carrier status for the virus. Some 10 to 15% of carriers later develop 
serious liver disease. The morbidity is substantial and will further add to our burden.  
 
HIV was first reported in Malaysia in 1986 with 3 cases. It has since exponentially grown 
peaking in 2002 when the number recorded was 51256 with six thousand deaths. It is 
predicted that in 2015, there will be 300000 people with HIV in the country, based on the 
current trend. Studies have however also suggested that cases of HIV are grossly under 
reported with estimates saying that for every reported case, there were 3-4 that go 
unreported. Thus, if we assume that for every reported HIV case in Malaysia, there are 3 
others unreported, in 2015, 1 million Malaysian will be people living with HIV/AIDS 
(PLWHA). Almost 80% of PLWHA are Malays. Thus, in terms of the Malay population 
that makes up about 50% of the current Malaysian population 1.2% of Malays now are 
PLWHA and this will rise to 6% in 2015. The impact of this on the demography of the 
Malaysian population can be staggering because these PLHA will die prematurely thus 
reducing the relative proportion of the Malays in the Malaysian population. More than 
two thirds of the 60,000 Malaysian PLWHA’s are injecting drug users and almost one in 
five injecting drug users in Malaysia is already infected with HIV.  (National Anti Drug 
Institution Report, 2008). 
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Figure 1.2: Consequences of HIV/AIDS in Malaysia 
 
In many circumstances illicit opiate use and criminal behaviour are also linked. Users 
commit crime to obtain money to maintain their habits and some commit crime under the 
influence of drugs. There is also an overlap between factors associated with the 
development of criminal behaviour, and factors associated with the initiation of illicit 
drug use. The drug using communities are also frequently “closed” and “fringed” 
communities with their own sub-cultures. They are frequently in the fringes of main-
stream societies with added social stigmas and discrimination that will add to the 
problems of criminality and social break down. 
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In Malaysia and in most countries, drug use problems are treated as a criminal/law 
enforcement issue with zero tolerance to drugs. Thus, in Malaysia, the approach to illicit 
drug use is primarily aimed at abstinence. A lot of emphasis is put on “rehabilitation”, 
either voluntary or otherwise. Drug users are regularly rounded up by the authorities and 
some are sent for “rehabilitations” at the AADK-run rehabilitation centres (Pusat 
Serenti). This strategy is aimed at inducing abstinence in drug users through cold turkey 
and social-behavioral approaches, generally by non-medical personnel. Many countries 
have attempted this but generally the success rate is only about 10%, an experience 
shared by Malaysia. In 2002, 14163 were incarcerated at the 28 rehabilitation centers run 
by AADK and this represented only about 6% of the estimated number of drug users 
then. Thus apart from the high failure rate, this effort can only reach a small percentage 
of the drug users in the country although the money spent is tremendous. (National Anti 
Drug Institution Report, 2008). This surely is not a very cost-effective approach. The 
complication is, when drug users undergo treatment, the community expects them to 
achieve a drug-free lifestyle. It is therefore not surprising that many of the approaches 
taken are aimed at achieving a drug-free lifestyle, a delusion. While abstinence is an 
important long-term goal, to put it as the only goal reflects our poor understanding of the 
complexities of drug dependence. Drug dependence is a complex disease. The 
combination of physical, biological, psychological and social dimensions makes drug 
dependence a complex condition. For drug dependence to be successfully overcome, all 
these dimensions must be addressed at. For many of them, this may entail substantial 
physical, biological, psychological and lifestyle adjustments – a process that usually 
requires a long time. We cannot treat addiction today as we used to treat mental illness, 
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leprosy and tuberculosis in the olden days. The stigma faced by addicts today is probably 
no different from those faced by patients suffering from these illnesses before. 
 
There is no single effective treatment for the management of heroin dependence. 
Nevertheless, current evidence indicates that a broad range of treatment options are 
available that can substantially impact on the course of opiate dependence and its 
consequences. Drug substitution treatment (DST) is an example.  DST has been 
extensively investigated with hundreds of randomised clinical studies done. These studies 
consistently reported benefits for those in treatment. (National Instittutes of Health. 1997) 
For instance, there is overwhelming evidence that methadone maintenance is safe, 
effectively improves health outcomes, reduces crime and enhances social functioning 
while lowering the risk of HIV transmission.  
 
There is therefore a need to develop a broad range of community based treatment 
responses to manage heroin dependence in Malaysia. The rapid spread of HIV amongst 
injecting drug users in Malaysia further underscores the imperative to organise a 
comprehensive treatment approach. However, people in Malaysia may wish to see 
evidence from research undertaken in the local context. 
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1.3 How methadone Maintenance Treatment (MMT) works 
 
Methadone was developed by German scientists in the late 1930s. It was approved by the 
U.S Food and Drug Administration (FDA) in 1947 as a painkiller, and by 1950 oral 
methadone also was used to treat the painful symptoms of persons withdrawing from 
heroin (Payte, 1991; Rettig and Yarmolonsky, 1995; Joseph et al, 2000). 
 
In 1964, Dole’s husband and wife team discovered that continous daily doses of oral 
methadone were beneficial, allowing otherwise debilitated opioid addicts to function 
more normally (Dole, 1988; Joseph and Appel, 1993; Kreek, 1993; Payte and Khuri, 
1993; National Instittutes of Health, 1997; Payte et al, 2003; Stine et al, 2003). An 
adequate maintenance dose of methadone does not make the patient feel “high’ or 
drowsy, so the patient can generally carry on a normal life. Daily drug seeking to feed a 
habit ceases. 
  
Methadone can be taken once daily by mouth without the use of injection needles and 
this limits exposure to blood-borne-viruses (BBV) like hepatitis C and B and HIV. Its 
gradual, long-lasting effects eliminate drug hunger or craving. There is also little change 
in tolerance to methadone over time, so it does not take more of the drug to achieve the 
same results as it would be with short acting opiates like heroin and morphine. The 
euphoria-blocking effects of methadone cause undesirable effect to illicit opioid users 
and this will encourage them to stop taking their illicit opiates. If used properly, 
methadone is generally safe and non-toxic with minimal side effect (Dole, 1988; Joseph 
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and Appel, 1993; Kreek, 1993; Payte and Khuri, 1993; National Instittutes of Health, 
1997; Payte et al, 2003; Stine et al, 2003). 
 
Methadone mantainance therapy (MMT) is generally considered as corrective therapy, 
rather than as a “cure” for opioid addiction, and it had no or only limited efficacy in 
treating dependence on other substances of abuse (Joseph et al, 2000). This is the 
contentious point taken by methadone detractors. They object to methadone because they 
claim that methadone will replace one addiction to another although experts have never 
claimed that methadone is to cure opiate addiction. However, taken in optimal doses, 
methadone can correct the compulsive use of heroin and other opiates by addicts (Dole, 
1988). Furthermore, oral methadone has a demonstrated favorable safety profile when 
properly prescribed and used. Although it can sometimes cause cardiac arrhythmias, no 
other serious adverse reactions or organ damage have been specifically associated with 
continued methadone use extending more than 20 years in some patients. Minor side 
effects, such as constipation or excess sweating, may appear during the early days of 
treatment and are easily managed. Indeed, women stabilized on methadone generally 
have healthier pregnancies compared to current opiate users and their newborns also do 
not suffer lasting adverse consequences (Payte et al, 2003; Stine et al, 2003). 
Furthermore, methadone at appropriate doses does not hinder a patient’s intellectual 
capacities or abilities to perform tasks (Gordon, 1994).  
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For therapeutic success, adequate methadone dosing is critical. Dole’s original research 
discovered that 80 to 120 milligrams of methadone per day, on average, was an effective 
dose. Dozens of studies since then have demonstrated that dosing in that range resulted in 
superior treatment outcomes, such as better retention of patients in treatment and less 
illicit drug use (Payte and Khuri, 1993; Nadelman and Mc Neely, 1996; Stine et al, 
2003). Patients maintained on inadequately low doses are much more likely to use illicit 
opioids and respond poorly to therapy (Gordon, 1994). On the other hand, for a variety 
reasons such as, pharmacologic variability at the enzyme and receptor levels, high 
tolerance to opioids, physical condition, mental status, concurrent medications, or prior 
use of high-purity heroin, some patients require much higher daily methadone doses for 
treatment success, sometimes exceeding 200 mg/day or more (Leavitt, 2003; Payte et al, 
2003; Stine et al, 2003).   
 
Remaining in treatment for an adequate period of time is critical for treatment 
effectiveness. The appropriate duration for an individual depends on their problems and 
needs, but research indicates that for most drug users, the threshold of significant 
improvement is reached only after about three months in treatment, with further gains as 
treatment is continued. Because people often leave treatment prematurely, and premature 
departure is associated with high rates of relapse to drug use, programmes need strategies 
to engage and keep patients in treatment. 
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In general the impact of treatment should be viewed in terms of its capacity to: 
 improve the quality and quantity of life of the individuals who come into 
treatment; 
 improve the quality of life of their family; 
 reduce criminal justice expenditure through diversion away from prison; 
 reduce health and welfare costs; 
 reduce the costs incurred by victims of crime; and 
 Improve the social environment. 
 
In summary, MMT adds importantly to our ability to deal with the ever increasing 
menace of illicit drug use.   Methadone is a long-acting drug. It occupies the opiate 
receptors at a slow pace and this creates a steady level of opiate in the blood. This 
characteristic avoids the "high and low” levels that generally occur with short-acting 
opiate administrations. The resulting constant tolerance threshold, stabililises the patient's 
deranged homeostatic mechanism, caused by opiate use, the deranged cognitive and 
motor function is also stabilised, and normalcy is maintained. Furthermore, as MMT is 
taken orally once daily, it also eliminates the cycle associated with frequent injections 
and the complications associated with this practice, such as the transmission of BBV. 
Most guidelines advises gradual increase in methadone dose and this results in a gradual 
increase in the tolerance threshold enabling patient to develop a tolerance threshold 
sufficiently high that an injection of any amount of street opiate will not be able to 
produce euphoria, thus eliminating the reward for  injecting drugs. A high dose of 
methadone is usually required to achieve this effect and it averages 100 mg per day. The 
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stability so provided by MMT can serve as a platform for other treatment modalities and 
rehabilitative process can begin. When these principles are followed, MMT is effective, 
and the individual and society gains.  It is however unfortunate that these principles are 
rarely followed. Thus, although it the body of knowledge supports a daily dose of at least 
80 mg to 100 mg to abolish further craving for opiates, a big majority, including in 
Malaysia, are maintained on much lower doses. The believe that zero drug is best has 
similarly also led to frequent premature ceasation of MMT although evidence suggests 
that maintenance therapy for at least two years is required for the maximum probability 
of success. Ironically the encouragement to discontinue MMT quite often comes from 
care providers working in maintenance programs. Most caregivers often also do not try to 
adequately address the reasons why opiate was taken by the patient in the first place or 
the existence of coexisting psychiatric illnesses. This frequently results in increasing 
anxiety among patients that may explain their needs for other mood-altering drugs, such 
as the benzodiazepines. 
 
1.4 MMT Criticisms, Concerns and Regulation 
 
Methadone is a much maligned drug, both by physicians as well as the lay public. The 
reason for such a negative attitude is less than clear except for the fact that drug addiction 
has always been stigmatized and many views and believes that the only meaningful 
treatment of addiction is total abstinence. Arguably we can attribute the negative views of 
the lay public is due to their ignorance and inability to truly understand addictive 
behaviours. This however cannot be true with the physicians and other care givers as 
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literature, both scientific and lay, abounds that espouses the reasons and advantages of 
methadone. Their mistrust for methadone can even be looked as sinful as they betray the 
trust accorded to them by both the Government and the patients. Their ignoring of the 
basic principles will jeopardize all the gains that can potentially accrue from MMT. 
 
Physicians acting in this manner cannot hide behind their ignorance of pharmacologic 
principles. Their contention for not wanting to prescribe mood altering drugs too freely 
cannot also be supported as other similar medications such as the benzodiazepines are 
often freely prescribed by them and they too can produce severe psychologic and 
physiologic dependence. Methadone, if at all is only minimally associated with adverse, 
physiologic effects and it is a drug probably with the least side effects of any drug in a 
physician's pharmacologic armamentarium, when used appropriately. 
 
Through the years, MMT has attracted some negative attitudes and actions by critics. A 
segment of public opinion has opposed the use of methadone for treating opioid addition 
and political initiatives have even been enacted or proposed to thwart access to MMT 
(Ehlers, 1999; PRNewswire, 1999). Some even support the closing down MMT programs 
or instituting such strict regulations to make it difficult for people on methadone 
maintenance to hold jobs. Their contention is that persons on methadone are 
noncompliant and may sell their methadone, and may continue to use heroin. However, 
compliance rates for methadone maintenance are no less than those seen with other 
chronic disorders, such as diabetes, asthma, or hypertension. Indeed, they are much 
greater as the methadone is taken under direct supervision in most programs. Those who 
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sell their medication are few compared to those who function well when MMT is 
appropriately provided.  
 
Many people still perceive opioid dependence as a self-controllable “bad habit” and 
dismiss MMT as an effective, addictive-narcotic substitution therapy (Rettig and 
Yarmolonsky, 1995; National Institutes of Health, 1997) despite most authorities 
recognising that methadone is not merely a substitute for illicit opioids, and that MMT 
does not simply replace one addiction with another (U.S. General Accounting Office, 
1990; Zweben and Payte, 1990; Ehlers, 1999; ONDCP, 1999; Payte et al, 2003; Center 
for Substance Abuse Treatment, 2004; Krantz and Mehler, 2004). Although methadone 
can cause physical dependence, its steady and long-term action in the brain contrasts 
sharply with the disruptive cycle of “highs” and “lows” produced by short-acting opioids 
that lead to addictive behaviors (Kreek, 1993; Nadelman and Mc Neely, 1996; 
McCaffrey, 1999; Payte et al, 2003;). Methadone substitutes a stable existence for one of 
compulsive drug seeking and taking, criminal behavior, chronic unemployment and high-
risk sexual and drug-use behaviors (ONDCP, 1999). 
 
As alluded, for MMT to give the best benefits, adequate doses are required. 
Unfortunately, especially during the early days of MMT there were rapid clinic 
expansion of the MMT programs in the face of deceased funding (Kreek, 1993; D' Aunno 
and Pollack, 2002) and this unwittingly led to the use of low doses with the consequent 
poor results that in turn fed into the already sceptical public. Surveys have observed that a 
majority of U.S. MMT clinics once provided average methadone doses far below the 80 
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mg/day recommended minimum (D' Aunno and Pollack, 2002). There have been some 
improvements. Many  programs now achieve average doses of 80 mg/day or more 
although  many more patients still receive inadequate doses (D' Aunno and Pollack, 
2002; Leavitt, 2003) with the consequent poor response, just as would any individuals 
prescribed insufficient drug therapy for any chronic medical disorder (D' Aunno and 
Pollack, 2002; Stine et al, 2003) and such failures will be viewed negatively by the 
detractors. 
 
Malaysia is not spared the negative sentiments about MMT. Measures have however 
been taken to improve MMT in Malaysia at the primary care levels by the Governmental 
and non governmental (NGOs) agencies notably the Ministry of Health and the 
Malaysian AIDS Council and its partner organisations. The strategies include 
strengthening community organizations which often are weak and highly reliant on small 
numbers of dedicated individuals (many of whom volunteer their labour). Professionals 
in collaboration with policy makers and other stakeholder are also meeting to standardise 
the strategies such as in education, in needle syringe exchange programme, in MMT and 
in anti retroviral treatment (ARV).  
 
Preventive programmes for most at- risk populations are now widely implemented 
through community based and other civil society organizations. Nevertheless, many still 
have to struggle to secure adequate resources to do their work, to obtain adequate and 
sustainable funding and to increase human resources. Information and preparation time 
often prevent many volunteers from participating in national processes although their 
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counsel are now frequently sought. Supporting and strengthening such consultation will 
auger well for our efforts at continous improvement to our HIV response.  
 
As alluded, the expectation of the society as regards treatment of drug addiction is for the 
dug users to cease taking drugs. MMT is viewed as replacing one addiction for another. 
Thus stigma and discrimination remain troublesome and many drug users find it very 
difficult to reintrgrate themselves into the society. This may actually impact on the user’s 
views themselves as regards MMT. Continued discussions are carried out to minimise 
such negative views. 
 
1.5 Regulations and Accreditation Promote “Best Practices” 
 
In the U.S, MMT has been a tightly controlled medical specialty.with methadone itself 
being a highly regulated drug (Nadelman and Mc Neely, 1996; National Instittutes of 
Health, 1997). Revised Federal regulations however emphasized improved patient care 
and increased healthcare Practitioner discretion in meeting patients’ needs; particularly 
allowing more liberal methadone dosing and permitting qualified patients to take home 
doses for self-administration (CFR, 2001).  However, state and local regulations may be 
more stringent. Thus, as a component of the regulations, MMT programs must 
successfully complete accreditation process similar to that required of much larger 
healthcare organizations. Best-practice guidelines and standards have been developed, 
reflecting the latest evidence promoting excellence in the treatment of opioid addiction. 
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Results to date indicate that MMT program accreditation has been successful in 
improving  patient care, safety, and treatment outcomes (Krantz and Mehler, 2004).  
A similar approach has been taken in Malaysia with MMT and methadone being highly 
regulated. Not all doctors in Malaysia are authorized to prescribe methadone and even 
then, caps are put on the maximum number of patients a given doctor can have on his 
MMT program. Given the underlying sceptism people have on MMT, these stringent 
regulations and capping make access to methadone somewhat problematic to the average 
drug user. Continued efforts have to be made to change this mindset, to get MMT to be 
more freely available with the understanding that its primary goal is harm reduction 
rather then the reduction in opiate addiction. 
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1.6 Pharmacogenetic of Methadone.: An Overview                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: An overview of drug fate inside body 
 
 
 
 
 
Exogenous Opiod 
Metaboliser 
Transporter 
Receptor 
Transporter 
Metaboliser 
Elimination 
OPRM1 
µ-Opiod receptor 
ATP-binding cassette 
transporter 
Effect 
22 
 
Methadone is a synthetic opioid, used mainly as an analgesic, and a replacement for 
opiate in MMT. It was developed in Germany in 1937. Methadone acts on the opioid 
receptors and produces many of the same effects of morphine and heroin, the drugs it is 
replacing. In the treatment of opioid dependence, methadone has cross-tolerance with 
other opioids including heroin and morphine and a long duration of effect. Higher doses 
of methadone can block the euphoric effects of heroin, morphine, and similar drugs. As a 
result, properly dosed methadone patients can reduce or stop altogether their use of these 
substances.  
 
Methadone is a misunderstood drug and ignorance about it is commonplace. Even 
professionals, physicians and pharmacists who are supposed to be the “guardians” of 
MMT receive very little training about the very medication that they are responsible for. 
To compound the issue, addiction is mostly viewed not as a disease and its care is 
frequently relegated to the lay public, at least until very recently. In Malaysia, addiction 
has solely been under the charge of AADK, an agency that has mainly adopted a criminal 
approach to addiction. This has recently changed in Malaysia. Addiction is now 
recognized as a medical illness, under the purview of the medical professionals. 
Nevertheless, many in the medical profession only have a rudimentary understanding of 
addiction. Most physicians, pharmacists and nurses receive very little training about 
addiction and much less regarding methadone. Thus, generally, both medical and other 
care givers have very limited knowledge about addiction and much less about methadone. 
They have generally been taught to approach addiction as a character disorder and 
administer methadone as a substitute.  
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Methadone has variable pharmacology. It binds to the µ-opioid receptor, the NMDA 
ionotropic glutamate receptor to exert its effects. Its metabolism is mediated by several 
enzymes including CYP3A4, CYP2B6 and CYP2D6, enzymes that are polymorphic and 
hence exhibit great variability. It is mainly  administred through the oral route and 
adverse effects include hypoventilation, constipation and miosis, in addition to tolerance, 
dependence and withdrawal difficulties.  
 
As a full µ-opioid agonist, methadone exhibits all the opiate-like effects. Furthermore, its 
binding to the glutamatergic NMDA (N-methyl-D-aspartate) receptor makes it a receptor 
antagonist against glutamate which is the primary excitatory neurotransmitter in the CNS. 
NMDA receptors modulate long term excitation and memory formation and NMDA 
antagonists such as dextromethorphan (DXM), ketamine, tiletamine and ibogainehave 
been studied for their role in decreasing the development of tolerance to opioids and as 
possible for eliminating addiction/tolerance/withdrawal. It action on the NMDA has been 
proposed as a mechanism by which methadone decreases craving for opioids (Xiao et al, 
2001). 
 
Methadone is a lipophilic drug and requires biotransformation for elimination. It has a 
slow metabolism and is longer lasting than morphine-based drugs. Typically its 
elimination half-life ranges from 15 to 60 hours with a mean of around 22 hours. Due to 
the polymorphic nature of its metabolism, its metabolism rates vary greatly between 
individuals, up to a factor of 100. This variability is apparently due to genetic variability 
in the production of the associated enzymes CYP3A4, CYP2B6 and CYP2D6. Several 
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studies have been conducted to explain the intra-as well as inter-individual variability in 
methadone’s pharmacokinetic and clinical response. Typically, methadone is a substrate 
for several CYP 450 enzymes as well as P-glycoprotein (PGP). Many Single Nucleotide 
Polymorphisms (SNPs) have been reported to contribute to its variability. Furthermore, 
as it binds to µ-receptors, SNPs in OPRM gene that encodes for these receptors may 
contribute to the clinical response in MMT patients. Thus, SNPs in OPRM gene, CYP 
gene and ABCB1 (MDR1) gene may contribute to determine the clinical outcomes of the 
MMT (Lötsch et al, 2009). 
 
1.7 Role of Cytochrome P450 in Methadone metabolisms 
 
Methadone is available in most countries as a racemic mixture of (R) and (S) 
enantiomers, though most of the clinical effect is from (R) methadone. Methadone 
metabolism is mediated by several CYP 450 enzymes leading to the inactive 2ethylidene-
1,5-dimethyl-3,3diphenylpyrrolidine (EDDP) via N-demethylation pathway (Sullivan et 
al, 1973). It has been found that CYP3A4, CYP2B6, CYP2D6, CYP1A2, CYP2C8, 
CYP2C9, and CYP2C19 all have either major or minor involvement in methadone 
metabolism (Lanz and Thormann, 1996; Eap et al, 2001; Wang and DeVane, 2003; Eap 
et al, 2004; Gerber et al, 2004; Totah et al, 2007; Totah et al, 2008). This complexity has 
led to a great and unpredictable intra-individual as well as inter-individual variability 
causing a misleading interpretation for/of the pharmacokinetic data. Recently, it has been 
demonstrated that CYP3A4 and CYP2B6 are the main influential contributors to 
methadone’s metabolism. CYP2B6 shows stereoselectivity towards (S)-enantiomer, 
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whereas CYP2C19 shows stereoselectivity towards (R)enantiomer. CYP3A4 shows no 
stereoselectivity towards either (Gerber et al, 2004; Kharasch et al, 2004).  
 
Initial studies have shown that CYP3A4 is the major contributor for the metabolism of 
methadone. Accordingly, drugs that induce or inhibit CYP3A4 are considered interacting 
drugs. CYP3A4 activity is measured by the midazolam phenotyping test. It was shown 
that higher doses are required when high activity is evident (Shinderman et al, 2003). 
Unfortunately, it was shown that midazolam lacks the adequacy of specificity and 
sensitivity for CYP3A4. Furthermore, CYP3A4 activities were similar in patients 
receiving doses lower than 200 mg. The difference rose in patients for whom dosing was 
greater than 200 mg daily. Further, the expression of CYP3A4 is highly varied among 
individuals, indicating that these patients might have a higher clearance rate or more 
expressed enzymes rather than being rapid metabolizers. Moreover, CYP3A5 may 
constitute as much as 50 % of the total hepatic content of CYP3A in people who express 
it. This enzyme plays no role in the metabolism of methadone (Crettol et al, 2006). As a 
result, it has been suggested that CYP3A4 plays minimal role which significantly varies in 
terms of intra- as well as inter-individual basis.  
 
Most in-vivo studies have suggested a minor contribution of CYP2D6 in methadone 
metabolism (Wang and DeVane, 2003). CYP2D6 inhibitors, however, have shown 
relatively significant drug-drug interactions with methadone, and these include such as 
paroxetine, fluoxetine and fluroxamine (Eap et al, 1997; Iribarne et al, 1998; Begré et al, 
2002). In a study, patients were divided into: CYP2D6 poor metabolizers (PM), extensive 
